MX2015016344A - Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. - Google Patents
Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.Info
- Publication number
- MX2015016344A MX2015016344A MX2015016344A MX2015016344A MX2015016344A MX 2015016344 A MX2015016344 A MX 2015016344A MX 2015016344 A MX2015016344 A MX 2015016344A MX 2015016344 A MX2015016344 A MX 2015016344A MX 2015016344 A MX2015016344 A MX 2015016344A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- treatment
- imidazopyrrolidinone
- derivatives
- present
- Prior art date
Links
- LOROIKRUMJLRJU-UHFFFAOYSA-N 4,6-dihydro-1h-pyrrolo[2,3-d]imidazol-5-one Chemical class N1C=NC2=C1CC(=O)N2 LOROIKRUMJLRJU-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13169390 | 2013-05-27 | ||
| EP13177676 | 2013-07-23 | ||
| PCT/IB2014/061715 WO2014191894A1 (en) | 2013-05-27 | 2014-05-26 | Imidazopyrrolidinone derivatives and their use in the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015016344A true MX2015016344A (es) | 2016-03-01 |
Family
ID=50979826
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015016344A MX2015016344A (es) | 2013-05-27 | 2014-05-26 | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9890166B2 (enExample) |
| EP (2) | EP3004109A1 (enExample) |
| JP (1) | JP6373978B2 (enExample) |
| KR (1) | KR20160012194A (enExample) |
| CN (1) | CN105209467B (enExample) |
| AU (1) | AU2014272774B2 (enExample) |
| BR (1) | BR112015029491A2 (enExample) |
| CA (1) | CA2913697A1 (enExample) |
| EA (1) | EA029312B1 (enExample) |
| MX (1) | MX2015016344A (enExample) |
| WO (1) | WO2014191894A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2903881C (en) | 2013-03-15 | 2021-05-18 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| WO2014191894A1 (en) | 2013-05-27 | 2014-12-04 | Novartis Ag | Imidazopyrrolidinone derivatives and their use in the treatment of disease |
| CA2915622C (en) | 2013-06-21 | 2020-08-18 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| MX365864B (es) | 2013-06-21 | 2019-06-18 | Zenith Epigenetics Ltd | Inhibidores de bromodominio biciclicos novedosos. |
| EP3019502B1 (en) | 2013-07-08 | 2017-05-17 | Incyte Holdings Corporation | Tricyclic heterocycles as bet protein inhibitors |
| EA201690087A1 (ru) | 2013-07-31 | 2016-08-31 | Зенит Эпидженетикс Корп. | Новые квиназолиноны как ингибиторы бромодомена |
| HRP20221389T1 (hr) | 2013-10-18 | 2023-01-06 | Celgene Quanticel Research, Inc. | Inhibitori bromodomena |
| WO2015075665A1 (en) * | 2013-11-21 | 2015-05-28 | Novartis Ag | Pyrrolopyrrolone derivatives and their use as bet inhibitors |
| WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
| US9309246B2 (en) | 2013-12-19 | 2016-04-12 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| WO2015164480A1 (en) | 2014-04-23 | 2015-10-29 | Incyte Corporation | 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS |
| US9527864B2 (en) | 2014-09-15 | 2016-12-27 | Incyte Corporation | Tricyclic heterocycles as BET protein inhibitors |
| US10179125B2 (en) | 2014-12-01 | 2019-01-15 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
| WO2016087936A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Corp. | Substituted pyridinones as bromodomain inhibitors |
| CN107207474B (zh) * | 2014-12-11 | 2021-05-07 | 恒翼生物医药科技(上海)有限公司 | 被取代的杂环作为溴结构域抑制剂 |
| JP2017538721A (ja) | 2014-12-17 | 2017-12-28 | ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． | ブロモドメインの阻害剤 |
| GB201504694D0 (en) | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
| AR104259A1 (es) * | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| TW201722966A (zh) | 2015-10-29 | 2017-07-01 | 英塞特公司 | Bet蛋白質抑制劑之非晶固體形式 |
| AU2017220611A1 (en) | 2016-02-15 | 2018-08-30 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | TAF1 inhibitors for the therapy of cancer |
| SMT202300155T1 (it) | 2016-06-20 | 2023-07-20 | Incyte Corp | Forme solide cristalline di un inibitore di bet |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| CN110225755A (zh) | 2016-11-14 | 2019-09-10 | 分子医学研究中心责任有限公司 | Brd4抑制剂和抗叶酸剂的组合用于治疗癌症 |
| KR102515694B1 (ko) | 2017-01-10 | 2023-03-29 | 바이엘 악티엔게젤샤프트 | 해충 방제제로서의 헤테로사이클 유도체 |
| BR112019014270B1 (pt) | 2017-01-10 | 2023-12-26 | Bayer Cropscience Aktiengesellschaft | Derivados de heterociclo, seus usos, formulação agroquímica, e método para controlar pragas animais |
| CN110418790B (zh) * | 2017-03-06 | 2022-05-17 | 罗欣药业(上海)有限公司 | 作为p53-MDM2抑制剂的咪唑并吡咯酮化合物 |
| RU2753527C2 (ru) * | 2017-03-31 | 2021-08-17 | Новартис Аг | ДОЗА И СХЕМА ВВЕДЕНИЯ ИНГИБИТОРА ВЗАИМОДЕЙСТВИЯ HDM2 С p53 ПРИ ГЕМАТОЛОГИЧЕСКИХ ОПУХОЛЯХ |
| US11098017B2 (en) * | 2017-09-28 | 2021-08-24 | The General Hospital Corporation | Compounds for treating disorders associated with abnormal steroidogenesis |
| CN111683932A (zh) * | 2018-02-06 | 2020-09-18 | 上海海和药物研究开发有限公司 | 具有bet抑制活性的化合物及其制备方法和用途 |
| WO2019174576A1 (zh) * | 2018-03-12 | 2019-09-19 | 罗欣药业(上海)有限公司 | 咪唑并吡咯酮化合物及其应用 |
| BR112021017042A2 (pt) * | 2019-03-15 | 2021-11-16 | Nippon Soda Co | Composto, e, fungicida para agricultura ou horticultura |
| WO2021047466A1 (zh) * | 2019-09-12 | 2021-03-18 | 罗欣药业(上海)有限公司 | 一种p53-MDM2抑制剂的晶型及其制备方法 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| US20230247994A1 (en) | 2020-07-02 | 2023-08-10 | Bayer Aktiengesellschaft | Heterocyclene derivatives as pest control agents |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3829420A (en) | 1970-07-13 | 1974-08-13 | Sumitomo Chemical Co | 3,4-dihydro-2(1h)-quinazolinones and preparation thereof |
| US4099002A (en) | 1970-12-23 | 1978-07-04 | Sumitomo Chemical Company, Limited | Quinazolinone derivatives and a process for production thereof |
| JPS4822715B1 (enExample) | 1970-12-28 | 1973-07-07 | ||
| JPS5427356B2 (enExample) | 1972-03-31 | 1979-09-10 | ||
| US4258187A (en) | 1977-06-16 | 1981-03-24 | E. I. Du Pont De Nemours And Company | Process for preparing quinazolinone oxides |
| US4335127A (en) | 1979-01-08 | 1982-06-15 | Janssen Pharmaceutica, N.V. | Piperidinylalkyl quinazoline compounds, composition and method of use |
| JPS5721388A (en) | 1980-07-11 | 1982-02-04 | Nippon Nohyaku Co Ltd | Condensed pyrazole derivative |
| DE3420799A1 (de) | 1984-06-04 | 1985-12-05 | Bayer Ag, 5090 Leverkusen | Chromogene 4,4-diaryl-dihydrochinazolone, ihre herstellung und verwendung |
| AU2436792A (en) | 1991-08-16 | 1993-03-16 | Merck & Co., Inc. | Quinazoline derivatives as inhibitors of hiv reverse transcriptase |
| US5508300A (en) | 1994-01-14 | 1996-04-16 | Pfizer Inc. | Dihydro pyrazolopyrroles, compositions and use |
| ATE215084T1 (de) * | 1994-07-28 | 2002-04-15 | Byk Gulden Lomberg Chem Fab | Imidazopyridin-azolidinone |
| DE69738754D1 (de) | 1996-07-05 | 2008-07-17 | Cancer Rec Tech Ltd | Hemmer der interaktion zwischen p53 und mdm2 |
| JP2000503461A (ja) | 1996-10-28 | 2000-03-21 | エービービー パワー システムズ アクチボラゲット | 高圧直流送電系統用の海底電極 |
| HRP980143A2 (en) | 1997-04-09 | 1999-02-28 | Soo Sung Ko | 4,4-disubstituted-3,4-dihydro-2 (1h)-quinazolinones useful as hiv reverse transcriptase inhibitors |
| WO2000066560A1 (en) | 1999-05-04 | 2000-11-09 | American Home Products Corporation | Quinazolinone and benzoxazine derivatives as progesterone receptor modulators |
| JP2001302515A (ja) | 2000-04-18 | 2001-10-31 | Sumitomo Pharmaceut Co Ltd | ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤 |
| US6479499B1 (en) | 2000-06-28 | 2002-11-12 | National Science Council | 2-phenyl-4-quinazolinone compounds, 2-phenyl-4-alkoxy-quinazoline compounds and their pharmaceutical compositions |
| BR0113176A (pt) | 2000-08-10 | 2003-06-17 | Pharmacia Italia Spa | Compostos biciclo-pirazol, composições farmacêuticas compreendendo os compostos, uso dos compostos na fabricação de medicamentos, processos para a preparação dos compostos, coleção quìmica combinatória e métodos para o tratamento de mamìferos incluindo humanos utilizando os compostos |
| RU2305095C2 (ru) | 2001-12-18 | 2007-08-27 | Ф.Хоффманн-Ля Рош Аг | Цис-2,4,5-трифенилимидазолины и фармацевтическая композиция на их основе |
| EP1513522A2 (en) | 2002-01-18 | 2005-03-16 | Sri International | Methods of treating conditions associated with an edg receptor |
| AU2003235504A1 (en) | 2002-05-13 | 2003-11-11 | 3-Dimensional Pharmaceuticals, Inc. | Method for cytoprotection through mdm2 and hdm2 inhibition |
| US7119111B2 (en) | 2002-05-29 | 2006-10-10 | Amgen, Inc. | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use |
| WO2004014916A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Pyrimidine fused bicyclic metalloproteinase inhibitors |
| EP1631260A2 (en) | 2003-02-28 | 2006-03-08 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US20040214856A1 (en) | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US20040213264A1 (en) | 2003-04-25 | 2004-10-28 | Nortel Networks Limited | Service class and destination dominance traffic management |
| CA2536313A1 (en) | 2003-08-22 | 2005-03-03 | Takeda Pharmaceutical Company Limited | Fused pyrimidine derivative and use thereof |
| PT1663185E (pt) | 2003-09-22 | 2009-02-16 | Onepharm Res & Dev Gmbh | Prevenção e tratamento de perda óssea induzida por inflamação e/ou imunomediada |
| KR20060127413A (ko) | 2003-11-25 | 2006-12-12 | 카이론 코포레이션 | 항암제로서의 퀴나졸리논 화합물 |
| KR20080027969A (ko) | 2004-05-18 | 2008-03-28 | 에프. 호프만-라 로슈 아게 | 신규 ｃｉｓ-이미다졸린 |
| BRPI0511748A (pt) | 2004-06-01 | 2008-01-02 | Univ Virginia | composição farmacêutica, métodos para tratar cáncer e uma doença ou distúrbio associado com angiogênese em um indivìduo em necessidade, para inibir a proliferação de células endoteliais vasculares e cancerosas, e para preparar sc-2-71 e análogos do mesmo, rótulo de fotoafinidade de sc-2-71, método para interromper a polimerização dos microtúbulos em uma célula, e para identificar um análogo, análogo, e, kit para administrar uma composiçaõ farmacêutica a um indivìduo |
| GB0419481D0 (en) | 2004-09-02 | 2004-10-06 | Cancer Rec Tech Ltd | Isoindolin-1-one derivatives |
| US20060069085A1 (en) | 2004-09-28 | 2006-03-30 | Rulin Zhao | Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
| US20060160869A1 (en) | 2005-01-05 | 2006-07-20 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| EP1868685A2 (en) | 2005-03-18 | 2007-12-26 | onepharm GmbH | 11ß-HYDROXYSTEROID DEHYDROGENASES |
| WO2006100038A1 (en) | 2005-03-23 | 2006-09-28 | Syngenta Participations Ag | Triazolopyrimidine derivatives useful as fungicides |
| US7576082B2 (en) | 2005-06-24 | 2009-08-18 | Hoffman-La Roche Inc. | Oxindole derivatives |
| EP1963326A1 (en) | 2005-12-12 | 2008-09-03 | NERVIANO MEDICAL SCIENCES S.r.l. | Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors |
| WO2007096334A1 (en) | 2006-02-24 | 2007-08-30 | Pfizer Italia Srl | Pyrrolopyrrolones active as kinase inhibitors |
| DE102006016426A1 (de) | 2006-04-07 | 2007-10-11 | Merck Patent Gmbh | Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren |
| AU2007260040A1 (en) | 2006-06-14 | 2007-12-21 | 4Sc Ag | Pyrazolopyrimidones |
| US8222288B2 (en) | 2006-08-30 | 2012-07-17 | The Regents Of The University Of Michigan | Small molecule inhibitors of MDM2 and the uses thereof |
| WO2008034039A2 (en) | 2006-09-15 | 2008-03-20 | Nexuspharma Inc. | Novel tetrahydro-isoquinolines |
| WO2008045529A1 (en) | 2006-10-12 | 2008-04-17 | Serenex, Inc. | Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases |
| TW200843739A (en) | 2007-03-30 | 2008-11-16 | Shionogi & Co | Novel pyrrolinone derivative and composition containing the same |
| WO2008130614A2 (en) | 2007-04-20 | 2008-10-30 | University Of Pittsburg-Of The Commonwealth System Of Higher Education | Selective and dual-action p53/mdm2/mdm4 antagonists |
| AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| UY31982A (es) | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas |
| JP5637562B2 (ja) | 2008-09-25 | 2014-12-10 | 塩野義製薬株式会社 | 新規ピロリノン誘導体およびそれを含有する医薬組成物 |
| JP2012505231A (ja) | 2008-10-08 | 2012-03-01 | ブリストル−マイヤーズ スクイブ カンパニー | アゾロピロロンメラニン凝集ホルモン受容体−１アンタゴニスト |
| EP2376495A4 (en) | 2008-12-08 | 2012-10-31 | Vm Pharma Llc | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS |
| WO2010075270A1 (en) | 2008-12-22 | 2010-07-01 | Incyte Corporation | 4, 6-disubstituted 2-amino-pyrimidines as histamine h4 receptor modulators |
| US20120208204A1 (en) | 2009-06-03 | 2012-08-16 | The Brigham And Women's Hospital, Inc. | Compositions and Methods for Inhibiting Tumor Growth |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| CU24130B1 (es) | 2009-12-22 | 2015-09-29 | Novartis Ag | Isoquinolinonas y quinazolinonas sustituidas |
| CN102199152A (zh) * | 2010-03-25 | 2011-09-28 | 高大新 | 杂环咪唑类磷脂激酶抑制剂 |
| US9085582B2 (en) | 2010-06-22 | 2015-07-21 | Glaxosmithkline Llc | Benzotriazolodiazepine compounds inhibitors of bromodomains |
| CA2811025C (en) * | 2010-09-10 | 2018-07-17 | Shionogi & Co., Ltd. | Hetero ring-fused imidazole derivative having ampk activating effect |
| US20120065210A1 (en) | 2010-09-15 | 2012-03-15 | Xin-Jie Chu | Substituted hexahydropyrrolo[1,2-c]imidazolones |
| GB201016880D0 (en) | 2010-10-07 | 2010-11-17 | Riotech Pharmaceuticals Ltd | Phosphodiesterase inhibitors |
| CA2817585A1 (en) | 2010-11-12 | 2012-05-18 | The Regents Of The University Of Michigan | Spiro-oxindole mdm2 antagonists |
| EP2705039B1 (en) | 2011-05-04 | 2017-07-26 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| WO2012174487A2 (en) * | 2011-06-17 | 2012-12-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| EP2721008B1 (en) | 2011-06-20 | 2015-04-29 | Novartis AG | Hydroxy substituted isoquinolinone derivatives as p53 (mdm2 or mdm4) inhibitors |
| EP2721007B1 (en) | 2011-06-20 | 2015-04-29 | Novartis AG | Cyclohexyl isoquinolinone compounds |
| WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2013033270A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same |
| CN104080787B (zh) | 2011-11-29 | 2016-09-14 | 诺华股份有限公司 | 吡唑并吡咯烷化合物 |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| US8815926B2 (en) | 2012-01-26 | 2014-08-26 | Novartis Ag | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases |
| US20130281397A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US20130281399A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| US20130281396A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| CN104334526A (zh) | 2012-04-20 | 2015-02-04 | 艾伯维公司 | 异吲哚酮衍生物 |
| US9365576B2 (en) | 2012-05-24 | 2016-06-14 | Novartis Ag | Pyrrolopyrrolidinone compounds |
| WO2014191894A1 (en) | 2013-05-27 | 2014-12-04 | Novartis Ag | Imidazopyrrolidinone derivatives and their use in the treatment of disease |
-
2014
- 2014-05-26 WO PCT/IB2014/061715 patent/WO2014191894A1/en not_active Ceased
- 2014-05-26 JP JP2016516276A patent/JP6373978B2/ja not_active Expired - Fee Related
- 2014-05-26 AU AU2014272774A patent/AU2014272774B2/en not_active Ceased
- 2014-05-26 MX MX2015016344A patent/MX2015016344A/es unknown
- 2014-05-26 US US14/892,616 patent/US9890166B2/en not_active Expired - Fee Related
- 2014-05-26 EP EP14731798.6A patent/EP3004109A1/en not_active Withdrawn
- 2014-05-26 BR BR112015029491A patent/BR112015029491A2/pt active Search and Examination
- 2014-05-26 KR KR1020157036223A patent/KR20160012194A/ko not_active Withdrawn
- 2014-05-26 EA EA201592256A patent/EA029312B1/ru not_active IP Right Cessation
- 2014-05-26 CA CA2913697A patent/CA2913697A1/en not_active Abandoned
- 2014-05-26 CN CN201480028176.6A patent/CN105209467B/zh not_active Expired - Fee Related
- 2014-05-26 EP EP18173244.7A patent/EP3412675A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014191894A1 (en) | 2014-12-04 |
| AU2014272774A1 (en) | 2015-11-26 |
| EP3004109A1 (en) | 2016-04-13 |
| US20160108047A1 (en) | 2016-04-21 |
| AU2014272774B2 (en) | 2016-12-08 |
| US9890166B2 (en) | 2018-02-13 |
| CN105209467B (zh) | 2018-06-08 |
| KR20160012194A (ko) | 2016-02-02 |
| JP2016520116A (ja) | 2016-07-11 |
| EP3412675A1 (en) | 2018-12-12 |
| JP6373978B2 (ja) | 2018-08-15 |
| CA2913697A1 (en) | 2014-12-04 |
| EA029312B1 (ru) | 2018-03-30 |
| EA201592256A1 (ru) | 2016-04-29 |
| BR112015029491A2 (pt) | 2017-07-25 |
| CN105209467A (zh) | 2015-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018501807A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseas | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| MX2020011652A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| MX2015008975A (es) | Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn). | |
| MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
| MX2016006667A (es) | Derivados de pirrolo-pirrolona y su uso como inhibidores. | |
| PH12016500756A1 (en) | Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors | |
| CY1124251T1 (el) | Παραγωγα καρβοξαμιδιου | |
| PH12019500328A1 (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
| MX2017012295A (es) | Derivados formilados n-heterociclicos como inhibidores de fgfr4. | |
| PH12019500849A1 (en) | Naphthyridinone derivatives and their use inthe treatment of arrhythmia | |
| EA201692298A1 (ru) | Производные карбоксамидов | |
| PH12020550763A1 (en) | Pyridinone derivatives and their use as selective alk-2 inhibitors | |
| TN2014000060A1 (en) | Benzothiazolone compound | |
| PH12019500327A1 (en) | Indazole compounds for use in tendon and/or ligament injuries | |
| PH12016502247A1 (en) | Carboxamide derivatives |